Biocon has informed that it enclosed the press release titled ‘Biocon Limited signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda® (Liraglutide) in Mexico with Medix.’ The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.